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Abstract
Histamine is one of the most important biogenic amines in medicine and biol-
ogy but its role in allergy, autoimmune and neoplastic diseases has not yet been
fully defined. The last few years have brought many discoveries concerning
important modulatory effects of histamine and its receptors on basic mecha-
nisms of the immunological processes. The role of histamine H1 and H2 recep-
tors in immunomodulation has been established. The immunomodulatory func-
tion of a newly described histamine H4 receptor has been revealed. One of the
most important modulatory effects of histamine currently studied is its influ-
ence on T lymphocyte differentiation and function. Our present knowledge sug-
gests that histamine may have a wider influence on various immunological
processes than is now accepted; therefore, we need further studies to fully clar-
ify the role of histamine and its receptors. This knowledge can bring new ther-
apeutic solutions in allergies, autoimmune diseases and malignancies.
Key words: histamine, receptors, inflammation, T lymphocytes, immunomodula-
tion, antihistamines.
Introduction
Histamine has been widely described throughout the twentieth cen-
tury. It was synthesized in 1907, 3 years after Dale described its vasodi-
lating effect. Since then, many biological functions of histamine have been
characterized, new receptors, beginning with histamine H1 receptors [1],
have been described, and intracellular effects of histamine receptors have
been explained. The knowledge led to the synthesis of medication used
in therapy of allergic and nonallergic diseases. At the end of the twenti-
eth century a number of scientists thought that the role of histamine in
allergy was well and nearly completely explained.
The discovery of a novel histamine receptor in 2000 and its character-
ization [2] was a signal for the need to accelerate studies on histamine
functions. Succeeding years brought many discoveries concerning the role
of the new histamine receptor. At the same time, new research showed
important modulatory effects of histamine and its receptors on basic mech-
anisms of immunological processes. 
Histamine as immunomodulator of lymphocyte activity 
The first evidence indicating histamine’s role in modulation of inflam-
matory processes was the inhibition of T lymphocyte cytolytic activity by
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histamine in mice. This effect, described by Plaut
et al., was blocked by the histamine H2/H3 recep-
tor antagonist burimamide, while the histamine H1
receptor agonists diphenhydramine and pyrilamine
had no influence on this phenomenon [1]. Further
studies confirmed the presence of histamine H2
receptors on T lymphocytes and showed that stim-
ulation of these receptors increases intracellular
cyclic adenosine monophosphate (cAMP) [3].
The role of histamine in suppression of periph-
eral blood mononuclear cell (PBMC) activity was
suggested in 1979 by Martinez et al., who also
showed differences between histamine effect on
PBMC obtained from allergic and healthy people
[4]. This study, although in the light of our present
knowledge burdened with significant methodolog-
ical flaws, showed that histamine can play a role in
modulation of inflammatory processes; and fur-
thermore, its effects on immunomodulation may
differ between allergic and healthy people. 
Another early finding, from a study conducted
by Rocklin et al. in 1980, was revealing the existence
of histamine receptors on mononuclear cells
appearing during allergen-specific desensitization
in ragweed allergic subjects with allergic rhinitis.
The presence of histamine receptors on mononu-
clear cells in peripheral blood, and the suppressive
role of these cells in inflammation, were confirmed
in animal models. Further studies showed that his-
tamine-binding peripheral blood T lymphocytes are
responsible for inhibition of inflammation [5]. In
1992, Shibata et al. described an increase of the
expression of histamine H2 receptors localized on
CD8+ CD25+ T lymphocytes after interleukin 2 (IL-2)
stimulation. Treatment of activated CD8+ lympho-
cytes with the H2 receptor antagonist cimetidine
significantly reduced the number of H2 receptors.
Suppressor lymphocytes induced by IL-2 were able
to suppress both IgG and IgM production, which
was reversible with cimetidine [6]. Further studies
showed that addition of histamine or histamine H2
receptor agonist to IL-2 significantly enhances the
accumulation of CD25+ T lymphocytes in peripher-
al blood in comparison with IL-2 administered alone.
Other studies indicated that histamine can increase
secretion of interleukin 5 (IL-5) from Th2 lympho-
cytes through histamine H2 receptors. Histamine
can also inhibit the adhesion of CD4+ T lymphocytes
to extracellular matrix proteins, fibronectin and
laminin, as histamine induces the increase of intra-
cellular levels of cAMP in these cells. This in turn
interferes with calcium influx-associated events that
occur during T cell activation. The above mechanism
is supported by the finding that T cell adhesion was
also inhibited by pharmacological inducers of cAMP .
Histamine exerts its suppressive effect on adhesion
of T lymphocytes via their H2 receptors, as pre-treat-
ment with H2 antagonists prevented this inhibito-
ry effect [7] (Figure 1).
In 1997, Lagier et al. tried to assess the influence
of histamine on various subpopulations of Th lym-
phocytes (Th1, Th2 and Th0) obtained from
bronchial biopsy or peripheral blood in atopic sub-
jects. They found that histamine inhibits IFN-γ pro-
duction by Th1-like lymphocytes, especially from
bronchial biopsy, but has no effect on IL-4 release.
Regarding Th0 clones, histamine inhibits IL-4 pro-
duction in a dose-dependent manner and causes
a slight decrease in IFN-γ production, but has no
effect on Th2-like lymphocytes. The study showed
that histamine has no significant effect on IL-5 pro-
duction. The H2 receptor antagonist ranitidine com-
pletely reverses the inhibition of IL-4 and IFN-γ pro-
duction, whereas the agonist dimaprit mimics this
effect. In contrast, H1 and H3 receptor agonists and
antagonists did not influence IL-4 and IFN-γ pro-
duction. These data demonstrated that histamine
via H2 receptors has different effects on IL-4 and
IFN-γ release from T helper lymphocytes depend-
ing on their phenotype. Histamine H2 receptor
stimulation can also lead to proliferation of acti-
vated T lymphocytes [8].
In 1998, Elenkov et al. observed that histamine
suppresses interleukin 12 (IL-12) and stimulates IL-10
secretion via stimulation of H2 receptors on periph-
eral monocytes, which leads to cAMP elevation.
Interleukin-12 stimulates the Th1 immune response,
whereas IL-10 is thought to lead to maturation of
dendritic cells (DC) into a phenotype which induces
Treg and stimulates the Th2 immune response. The
observed changes may result in a shift of Th1/Th2
balance toward Th2 dominance [9]. 
The role of histamine receptor-bearing T
lymphocytes in autoimmune reactions 
and malignancies
Besides stimulating suppressor T lymphocyte
activity, histamine can also partially and reversibly
inhibit cytolytic activity of T lymphocytes. This phe-
Figure 1. Effects of histamine action on T lympho-
cytes
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nomenon, demonstrated by Khan et al., depends
on histamine H2 receptor stimulation [10]. Some
data suggest that histamine protects natural killer
(NK) cells and T lymphocytes against oxygen radi-
cal-induced dysfunction and apoptosis through H2
receptors, and maintains their activation by IL-2 and
other lymphocyte activators. Additionally, histamine,
again via H2 receptors, binds to monocytes and
macrophages, which suppresses the activity of
NADPH oxidase, a key enzyme in oxygen radical for-
mation [11].
Some of the evidence for the role of histamine
H2 receptors in suppressing inflammatory process-
es was obtained by revealing the lack of H2 recep-
tor-bearing T lymphocytes in patients with histio-
cytosis X. The lymphocyte abnormalities were
reversed in vitro after incubation in a crude extract
of calf thymus gland, and therefore all patients were
treated with daily intramuscular injections of this
extract. A positive clinical response was associated
with an increase in the number of H2 receptor-bear-
ing T lymphocytes to normal levels and with cor-
rection of other immunological abnormalities. At
the same time, Mavligit et al. showed that hista-
mine H2 receptor stimulation inhibits T lymphocyte
induced graft versus host disease (GVHD). In this
study, addition of the histamine H2 receptor
inhibitor cimetidine caused a relapse of GVHD
because of defective suppressive T cell function [11]. 
Further studies on the role of histamine stimu-
lation via H2 receptors localized on suppressor T
lymphocytes showed its positive function of extin-
guishing autoimmune inflammatory reactions in
Graves disease, as well as possible unfavourable
effects of accelerating the growth of lethal tumours,
studied in a murine model. Gorczynski et al. con-
firmed that H2 receptor-bearing T lymphocytes par-
ticipate in stimulating malignant tumour growth in
mice. They also showed that addition of a selective
H2 receptor antagonist prevents this effect because
of suppressor T lymphocyte activity inhibition [12].
Histamine also reduces ICAM-1 expression and
cytokine production in human mixed lymphocyte
reaction stimulated with IL-18 through histamine
H2 receptors, whereas histamine alone did not
show any effects on these responses in the absence
of IL-18 [13, 14]. Histamine was also found to
enhance the immune suppressive effects of trans-
forming growth factor-β on T lymphocytes, acting
by the same receptor [13]. In some autoimmune dis-
eases, such as minimal change nephrotic syndrome,
the number of suppressor T lymphocytes bearing
histamine H2 receptors is reduced, but treatment
with glucocorticosteroids elevates it to a level
observed in healthy individuals [15]. The important
contribution of histamine in extinguishing autoim-
mune inflammation was recently confirmed in
a murine model by Musio et al. [16].
Functional antagonism between histamine H1
and H2 receptors localized on T lymphocytes
In 1981, Rocklin and Haberek-Davidson reported
the presence of H2 receptor and absence of hista-
mine H1 receptors on PBMC responsible for hista-
mine-dependent inhibition of inflammation [17].
The same year, Lima and Rocklin revealed the mod-
ulatory role of PBMC histamine stimulation on
immunoglobulin IgG production [18]. However, the
non-specific experimental model of inflammation
selected by the authors was unable to answer the
following important questions: which of the PBMC
suppressive cells contain histamine H2 receptors in
their membrane, and what is their role in in vivo
processes?
A study on the regulation of allergic inflammation
conducted by Beer et al. revealed essential differ-
ences in the activities of T lymphocyte subpopula-
tions between atopic and healthy subjects. In that
study, the authors showed that PBMC from atopic
subjects generate less histamine-induced suppres-
sor activity than from non-atopic, healthy subjects.
The percentage of T lymphocytes bearing histamine
H2 receptors was lower in the atopic group than in
the control group, but the percentage of cells with
H1 receptors was the same in both groups. In the
atopic subjects, the functional suppressor-cell abnor-
mality positively correlated with the decreased phe-
notypic expression of histamine H2 receptors. Non-
atopic control subjects with systemic mastocytosis
had normal functional and phenotypic data, sug-
gesting that chronic activation of atopic T lympho-
cytes in vivo by circulating histamine does not
explain the abnormal histamine-induced suppressor
response observed in atopics [19]. This phenomenon
was confirmed by Zak-Nejmark et al. in 1991. They
found that lymphocytes from atopic subjects showed
a statistically significant decrease in the binding of
the H2 receptor antagonist ranitidine. In addition,
lymphocytes from atopic and control subjects had
similar capacity of H1 receptor antagonist promet-
hazine binding. The ratio of the amount of H1 and
H2 antagonists, bound to lymphocytes from atopic
and healthy subjects, was calculated by the authors,
and the difference between the values in the group
of atopic (2.55) and control subjects (1.55) was sta-
tistically significant [20]. In the same year, Chinese
authors published results of a study in which iden-
tification and quantitative analysis of specific hista-
mine H1 and H2 receptors on lymphocytes were per-
formed and histamine-induced suppressor cell
activity was examined using 3H-histamine radioli-
gand-binding assay. Peripheral lymphocytes from
asthmatic subjects generated less histamine-induced
suppressor activity than those from healthy individ-
uals. In asthmatics, the functional suppressor cell
abnormality positively correlated with the decreased
quantity of H2 receptors on the lymphocytes [21].
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Consecutive studies brought data suggesting
antagonism between histamine H1 and H2 recep-
tors localized on T lymphocytes. Stimulation of his-
tamine H1 receptors led to a decrease of T lym-
phocyte suppressor activity. Stimulation of
histamine H2 receptors localized on these cells led
to an increase of inflammation suppression. These
phenomena were described in many publications
based on in vitro studies in human and rodent
blood cells [22]. Data obtained from in vivo studies
are much more difficult to interpret. For example,
histamine causes inhibition of immunoglobulin syn-
thesis through stimulation of histamine H1 recep-
tors. This effect is independent of histamine H2
receptor stimulation and probably caused by indi-
rect induction of glucocorticosteroid excretion from
suprarenal glands. Histamine interacts with H1
receptors and causes the release of adrenocorti-
cotropic hormone (ACTH) from pituitary glands. An
increased serum level of glucocorticosteroids leads
to inhibition of the synthesis of antibodies [23]. In
another study, histamine via H2 receptors caused
a decrease in antibody production after immuniza-
tion in mice [24]. 
In 1983, Weinstock et al. proved that histamine
H2 receptors suppress and H1 receptors stimulate
the granulomatous response of Schistosoma man-
soni-infected mice. They also showed that sup-
pression of the response depends on stimulation
of histamine H2 receptors on suppressor T lym-
phocytes, and stimulation of the response is asso-
ciated with activation of histamine H1 receptors,
localized on numerous cells of the granulomas,
including T helper lymphocytes [25]. At the same
time, other researchers revealed that histamine, by
interaction with histamine H2 receptors on T lym-
phocytes, induces the production of a cytokine
called histamine-induced suppressor factor (HSF).
The HSF inhibits lymphocyte proliferation and the
production of lymphokine and a cytokine called lym-
photactic factor (LCF), while cells that bear hista-
mine H1 receptors produce lymphocyte migration
inhibition factor (LMIF) [26]. In 1987, Schnaper et al.
described that secretion of a cytokine called solu-
ble immune response suppressor (SIRS) from
human T lymphocytes was stimulated by histamine
H2, but not H1 receptors [27].
Further studies have shown more differences in
cytokine secretion after stimulation of H1 or H2
receptors. In the study of Plaut et al., histamine, act-
ing on cytotoxic T lymphocytes, inhibited activity
of these cells through increase of intracellular cAMP
in mice [28]. According to our current knowledge,
this effect was associated with stimulation of his-
tamine H2 and H4 receptors, which causes increase
of adenyl cyclase activity. Increase of intracellular
cAMP after histamine H2 receptor stimulation can
be enhanced by activation of T lymphocytes by
interleukin 2 (IL-2) [29]. The studies also showed
differences in localization of histamine H1 recep-
tors between various subpopulations of T lympho-
cytes, as twice as many histamine H1 receptors
were expressed by CD8+ T lymphocytes as com-
pared to CD4+ T lymphocytes. The Th1 lymphocytes
show predominant expression of H1 receptors,
while Th2 lymphocytes show increased expression
of H2 receptors. Histamine enhances Th1-type
responses by triggering the H1 receptors, whereas
both Th1 and Th2-type responses are negatively reg-
ulated by H2 receptors, because of the activation
of different biochemical intracellular signals [30]. In
mice, deletion of H1 receptors results in suppres-
sion of IFN-γ and dominant secretion of Th2
cytokines (IL-4 and IL-13). The H2 receptor-deleted
mice showed up-regulation of both Th1 and Th2
cytokines. In addition, histamine stimulation
induced IL-10 secretion through H2 receptors.
Increased IL-10 production in both DC and T lym-
phocytes may account for an important regulatory
mechanism in the control of inflammatory func-
tions through histamine. In accordance with this
phenomenon, it was demonstrated that histamine
supports the suppressive effect of transforming
growth factor β (TGF-β) on T lymphocytes via H2
receptors [13]. The Th2 lymphocytes are more affect-
ed by histamine-enhanced TGF-β suppression,
which is important for the regulation of allergen-
specific T lymphocytes in allergic immune respons-
es. Then, stimulation of the T lymphocyte function
engaged in suppression of inflammation by selec-
tive stimulation of histamine H2 receptor on rat
T lymphocytes was questioned by Binderup. How-
ever, the results of his study are also questionable,
as the selective H2 receptor antagonist did not
reverse the effects of selective stimulation [26].
Most studies show that histamine H2 receptor local-
ized on T lymphocytes has an inhibitory effect on
inflammation and an enhancing effect on sup-
pressive processes leading to reduction of inflam-
mation (Figure 1).
In 2001, Jutel et al. revealed that histamine H1
and H2 receptor densities significantly differ
between Th1 and Th2 lymphocytes. They also
affirmed that Th1-type responses are enhanced by
histamine, whereas Th2-type responses are nega-
tively regulated, due to different intracellular sig-
nals generated by histamine stimulation. They
showed that deletion of H1 receptors results in sup-
pression of INF-γ and dominant secretion of the Th2
cytokines interleukin 4 (IL-4) and interleukin 13 
(IL-13) in mice. Mutant mice lacking H2 receptors
showed upregulation of both Th1 and Th2
cytokines. Relevant to T cell cytokine profiles, mice
lacking H1 receptors displayed an increased specif-
ic antibody response with increased immunoglob-
ulin E (IgE) and IgG1, IgG2b and IgG3 compared with158 Arch Med Sci 1, February / 2012
mice lacking H2 receptors. According to the authors,
these findings account for an important regulato-
ry mechanism in the control of inflammatory func-
tions through effector-cell-derived histamine [31].
The same year, Osna et al. showed that histamine
stimulates secretion of interleukin 10 (IL-10) from
Th2 lymphocytes through histamine H2 receptors.
Further results of the Osna group were different
from Jutel’s, suggesting that histamine enhanced
IL-13 secretion and mRNA levels in Th2 lymphocytes
via histamine H1 and H2 receptors in a dose-depen-
dent manner. They also revealed that pre-treatment
of Th2 lymphocytes with IL-12 reverses histamine’s
effects on IL-13 secretion in mice from stimulatory
to inhibitory [32].
Further important information about the func-
tion of histamine receptors were brought about by
the studies of Mazzoni et al., who showed that his-
tamine, coupled by a maturation signal, acts direct-
ly upon immature dendritic cells (iDCs), profound-
ly altering their T cell polarizing capacity. They
demonstrated that iDCs express two active hista-
mine receptors, H1 and H2. Histamine did not sig-
nificantly affect the lipopolysaccharide (LPS) driven
maturation of iDCs with regard to phenotypic
changes or capacity to prime native T lymphocytes,
but it dramatically altered the repertoire of
cytokines and chemokines secreted by mature DCs.
In particular, histamine, acting upon the H2 recep-
tor for a short period of time, increased IL-10 pro-
duction and reduced IL-12 secretion. As a result, his-
tamine-matured DCs polarized native CD4+ T
lymphocytes toward Th2 phenotype, contrary to
DCs that had matured in the absence of histamine
[33]. In a further study, Mazzoni’s group proved that
histamine acts on plasmacytoid DCs leading to
a marked down-regulation of IFN-α and TNF-α and
a moderate switch in their capacity to polarize
native T lymphocytes [34]. In the differentiation
process of type 1 DC from monocytes, H1 and prob-
ably H4 receptors can act as positive stimulants that
increase antigen-presentation capacity and proin-
flammatory cytokine production as well as Th1
priming activity. The important role of DC in regu-
lation of the activity and cytokine profile of Th lym-
phocytes was confirmed by Teusher and colleagues.
They observed that DC activity and cytokine pro-
duction are altered in mice lacking histamine H2
receptors, resulting in a decrease of IL-12 and IL-6
secretion and increase of MCP-1 secretion. These
phenomena  in vivo can considerably modify
cytokine secretion from Th1 and Th2 lymphocytes
in mice, observed in vitro by Jutel et al. [35]. 
Research on the role of histamine in modulation
of T lymphocyte function is complicated by hista-
mine autosecretion observed in both CD4+ and
CD8+ Th lymphocyte populations. In the study of
Sonobe et al., the authors assessed the role of his-
tamine autosecretion on cytokine profile in CD4+
and CD8+ lymphocytes [36], but their results are
different from observations on histamine from an
external source added to a suspension of cells.
Recently, Jelinek et al. showed that histidine decar-
boxylase knockout (HDC–/–) mice, which are genet-
ically histamine-free, exhibit predominantly a DC
cytokine pattern leading to Th1 lymphocyte polar-
ization [31].
New data obtained by McIlroy et al. show that
histamine causes an increase of chemokine CCL 17
and CCL 22 secretion and decrease of CXCL10 secre-
tion from iDC via H2 receptors [37]. Chemokines
CCL 17 and CCL 22 are chemoattractants of Th2 lym-
phocytes and CXCL10 is a chemoattractant of Th1
lymphocytes, so the phenomenon described above
leads to accumulation of Th2 lymphocytes and
a change in Th1/Th2 balance to the advantage of
Th2. The role of this phenomenon remains unclear,
because the main role in promoting the migration
of Th2 lymphocytes into sites of allergen exposure
falls to histamine H1 receptors. Therefore, T lym-
phocytes obtained from mice lacking these recep-
tors failed to confer airway inflammation or airway
hyperresponsiveness after allergen stimulation [38].
Despite one century of studies on the role of his-
tamine in physiology and pathogenesis of diseases,
our knowledge about histamine is still far from
complete. New questions about its participation in
immunological processes await answers. Its role in
regulation of lymphocyte function is most fasci-
nating. We are looking forward to an explanation
of the role of histamine H1 and H2 receptors locat-
ed on Th1 and Th2 lymphocytes in the pathogene-
sis of allergies and autoimmune diseases. So far,
data from different studies vary and do not author-
ize us to make final conclusions. Additional prob-
lems are caused by the heterogeneity of
immunomodulatory effects of known histamine
receptor ligands acting on the same histamine
receptors, observed by Ashenager et al. [39]. Other
issues awaiting explanation are the role of hista-
mine in macrophages, monocytes and dendritic
cells, in differentiation and maturation of various
subpopulations of T lymphocytes, as well as the role
of histamine in regulatory T lymphocyte (Treg) mat-
uration and function.
The role of histamine H4 receptor in 
modulation of lymphocyte function
Described in 2000 by Oda et al., the new hista-
mine H4 receptor was also found on T lymphocytes
[40]. The role of this receptor remains poorly under-
stood. The first evidence concerning its role in mod-
ulation of T lymphocyte function was delivered by
Gantner et al. in 2002. They observed that hista-
mine stimulation of human CD8+ T lymphocytes
purified from peripheral blood led to an increase in
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the release of IL-16. This increase was significantly
blocked by a histamine H2 receptor selective antag-
onist, or by a histamine H4 receptor antagonist.
They also showed that selective agonists of H2 and
H4 receptors were capable of inducing the release
of bioactive IL-16 from CD 8+ T lymphocytes [41].
Localization of H4 and other histamine receptors is
presented in Table I.
In 2006, Dunford et al. showed that H4 recep-
tor-deficient mice and mice treated with H4 recep-
tor antagonists exhibited decreased allergic lung
inflammation. In mutant mice lacking H4 receptors
the number of infiltrating lung eosinophils and lym-
phocytes was decreased and Th2 responses were
also reduced. Ex vivo restimulation of T lympho-
cytes showed decreases in IL-4, IL-5, IL-13, IL-6, and
IL-17 levels, suggesting that T cell functions were
disrupted. In vitro studies indicated that blockade
of H4 receptor on dendritic cells leads to reduction
in cytokine and chemokine production and limits
their ability to induce Th2 responses in T lympho-
cytes [42]. 
Clinical experience
In 1988, Italian authors described a randomized
trial, carried out in perennial atopic rhinitis. The
patients were divided into two homogeneous
groups and treated with histamine H2 antagonists
of different chemical structure: cimetidine and ran-
itidine. Identity of clinical and humoral results was
noted in the two groups. The results led the authors
to believe that the effects induced by these two
drugs are linked to the properties of H2 receptor
antagonists and not to other potential action. The
improvement in all subjective and objective param-
eters, decrease in total serum IgE, as well as the
delayed onset of clinical improvement, suggested,
according to the authors, that H2 receptor antago-
nists in fact induce a modulatory effect on the
T lymphocyte subpopulations with a variation in the
CD4+/CD8+ ratio towards the latter subpopulation
that identifies the suppressor lymphocytes [43]. This
study was questioned during the following years.
In 1992, Bury et al. showed that administration
of histamine (inhaled and intravenous) causes inhi-
bition of T cell proliferation. This effect occurred
also after administration of H2 receptor agonists
and was blocked by H2 receptor antagonists, while
histamine H1 receptor ligands had no effect on
T lymphocyte proliferation [44]. 
The long-term protection from honeybee stings
by terfenadine premedication during rush im  -
munotherapy with honeybee venom was analysed
in a double-blind, placebo-controlled trial. After an
average of 3 years, 41 patients were re-exposed to
honeybee stings. None of the 20 patients who had
been given H1 receptor antihistamine premedica-
tion, as compared to 6 of 21 given placebo, had
a systemic allergic reaction to the re-exposure by
either a field sting or a sting challenge. This highly
significant difference suggests that antihistamine
premedication during the initial dose-increase
phase may have enhanced the long-term efficacy
of immunotherapy. Expression of H1 receptor on T
lymphocytes is strongly reduced during ultra-rush
immunotherapy, which may lead to the dominant
expression and function of the tolerance-inducing
H2 receptor. This indicates a positive role of hista-
mine in immune regulation during systemic
immunotherapy [45]. However, since publishing
these data, no clinically significant effects of hista-
mine receptor modulation in allergen-specific
immunotherapy have been confirmed. The lack of
evident proof of the clinical effectiveness of hista-
mine receptor modulation leads to a conclusion that
the results of in vitro studies cannot be transferred
directly into a clinical setting.
Histamine H1 and H2 receptors during
pregnancy
Histamine receptors localized on T lymphocytes
are also believed to participate in maintenance of
pregnancy. Significantly reduced amounts of hista-
mine H1 receptors were noted during the second
trimester of pregnancy and this was associated
with a decreased H1/H2 receptor ratio [46]. Women
in the first and second trimester of pregnancy had
greater histamine-induced suppression of phyto-
haemagglutinin (PHA)-stimulated proliferation at
high concentrations of histamine, but less sup-
pression at the lower concentrations in comparison
to non-pregnant controls. In contrast, pregnant
women studied in the third trimester failed to
respond to any concentration of histamine. Recent-
ly, Pap et al. have shown that in the absence of
local histamine the cytokine balance is shifted
toward Th1 lymphocytes at the maternal-placental
interface, threatening pregnancy, because suc-
cessful pregnancy is closely related to polarization
toward a Th2 type immune response in mice [46].
Receptor Localization
H1 Vessels, smooth muscles, heart, central 
nervous system, macrophages, mastocytes,
eosinophils, and Th lymphocytes 
H2 Heart, stomach, uterus, central nervous system,
dendritic cells, neutrophils, macrophages, 
mastocytes, eosinophils, and Th lymphocytes 
H3 Respiratory tract, gastrointestinal tract and 
central nervous system
H4 Bone marrow, spleen, thymus, colon, 
mastocytes, CD8+ lymphocytes, and neutrophils
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Until now, the phenomena mentioned above
remain poorly understood and need further
research. Their clarification can bring progress in
comprehending spontaneous abortion and lead to
development of its prophylaxis or treatment.
Conclusions
Histamine is one of the best-known and one of
the most important biogenic amines in medicine
and biology. Histamine, released during inflamma-
tion, interacts with histamine receptors and trig-
gers vasodilatation, increases vascular permeabil-
ity, and interacts with inflammatory cells, thus
resulting in acute inflammatory and allergic
responses as well as the chronic phase of inflam-
mation. Its immunomodulatory effect, which
depends mostly on the influence of histamine on
T lymphocytes, is still not fully understood. Under-
standing histamine and histamine receptors as well
as their role in modulation of T cell activity is very
important for scientists and medical practitioners
and can bring some clues for further investigation
and for new therapeutic solutions in some illness-
es such as allergies, autoimmune diseases and
malignancies.
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